As discussed above, the aberrant tumor vasculature can counteract immunotherapy due to ill-delivery of the mAbs (as a result of the immature and badly structured blood vasculature) and restrain anticancer immune responses by favoring the presence of immunosuppressive immune cells (e.g., presence of MDSCs, M2 TAMs, and Treg cells (Fig. 4) over immunostimulatory immune cells (mainly CD8+ T cells). This evidence concerns the gene CD8A and neoplasm.